The abstract is read at the publisher; the summary is JClub's.
Systemic metabolic dysfunction is translated into MASLD progression through imbalanced insulin and glucagon, which disrupt glucose and lipid fluxes and promote hepatocellular stress and fibrosis.
- Why it matters: MASLD and MASH are liver consequences of whole-body metabolic dysfunction, but the specific metabolic and hormonal links that connect multi-tissue dysfunction to inflammation and fibrosis remain to be clarified.
- What they did: This review synthesizes evidence on metabolic and hormonal determinants of MASLD progression, emphasizing interactions among insulin resistance, adipose lipolysis, hepatic de novo lipogenesis, and hormone-driven substrate handling.
- The result: The integrated framework links metabolic disturbances to hepatocellular injury, inflammatory signaling, stellate cell activation, and chronic metaflammation, supporting mechanism-based therapeutic target discovery for MASLD and MASH.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.